People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Biotechnology, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mainz Biomed N.V. | — | Biotechnology | Series A | $14.9M | $122.3M | 2023 |
| Franchise Holdings International, Inc. | — | Manufacturing | Series A | $9.0M | $12.2M | 2024 |
William Caragol at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Caragol on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Heiner Dreismann | 1 | 6 |
| Paul Haber | 1 | 5 |
| Ned L. Siegel | 1 | 5 |
| MICHAEL JOHNSTON | 1 | 4 |
| Steven Rossi | 1 | 3 |
| Guido Baechler | 1 | 1 |
| Alberto Libanori | 1 | 1 |
| Moritz Eidens | 1 | 1 |
| Nicole Holden | 1 | 1 |
| Hans Hekland | 1 | 1 |
| Darin Leigh | 1 | 1 |
| Marco Messina | 1 | 1 |
| CRAIG LOVEROCK | 1 | 1 |
| Steve Raivio | 1 | 1 |
| Lorenzo Rossi | 1 | 1 |
| Phillip Freese | 1 | 1 |
| Gregory Tibbits | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.